Aflac (AFL) Q1 2026 earnings review
GAAP Earnings Explode on Investment Swing, But Core Operations Show Stability
Aflac's headline net income surged 3,414% YoY to $1.0 billion, but this dramatic acceleration is entirely an accounting artifact. The leap reflects $49M in net investment gains this quarter compared to a massive $963M loss a year ago. Beneath the noise, the core business remains remarkably stable: Adjusted earnings were flat (-0.6% YoY), but aggressive capital deployment—$1.0B in buybacks—drove a 5.4% increase in Adjusted EPS to $1.75. Operationally, Japan is experiencing a paradoxical split: new product sales are surging 25.5%, yet the total net earned premium continues to contract as older policy runoffs outpace new business. The U.S. segment provides a steady anchor with 3.5% premium growth, though an unfavorable Yen exchange rate remains a stubborn headwind.
🐂 Bull Case
Sales in Japan jumped 25.5% YoY, accelerating from a 15.7% pace in the prior quarter. New targeted products—like 'Anshin Palette' (medical), 'Miraito' (cancer), and 'Tsumitasu' (life)—are successfully re-engaging the market and capturing younger demographics.
The company remains an absolute cash-generating machine, returning $1.3 billion to shareholders this quarter ($1.0B in buybacks, $315M in dividends) and hiking its dividend by 5.2%—its 43rd consecutive year of increases.
🐻 Bear Case
Despite spectacular new sales figures, Aflac Japan's net earned premiums fell 3.8% (in Yen terms). The runoff of older, paid-up policies and reinsurance transactions continues to offset new customer acquisition.
The Yen weakened 2.8% YoY (to 156.87 vs 152.40), suppressing Aflac Japan's reported USD revenues by 6.4%. This structural FX exposure continually masks operational progress when translated to the consolidated bottom line.
⚖️ Verdict: ⚪
Neutral. Aflac's capital allocation strategy is elite, effectively manufacturing EPS growth through disciplined buybacks. However, until Japan's net earned premiums stop reversing and show definitive growth, the company relies heavily on cost control and financial engineering rather than true top-line expansion.
Key Themes
Japan Product Innovation Driving Accelerated Sales
Aflac is effectively revitalizing its aging Japanese customer base. Total new annualized premium sales in Japan accelerated rapidly to a 25.5% YoY increase (¥17.7 billion). This is directly attributable to strong market reception for 'Anshin Palette', the new medical insurance product launched in December, alongside the continued traction of 'Miraito' and 'Tsumitasu'. Management's strategy to segment products by life stage is clearly working.
The Growth Gap: Sales Rebound Has Not Fixed Premium Contraction
There is a glaring break in the trend: despite the 25.5% surge in new Japan sales, total Japan Net Earned Premiums decelerated from a 1.9% decline in 25Q4 to a 3.8% decline in 26Q1 (in Yen). Management cites the ongoing runoff of large blocks of paid-up limited-pay products and external reinsurance transactions. Until new business mathematically overtakes this structural runoff, the Japan segment cannot achieve true revenue growth.
U.S. Group Business Anchoring Stability
The U.S. segment continues to provide a stable, growing counterbalance to Japan's currency and runoff issues. U.S. Net Earned Premiums grew 3.5% YoY to $1.55 billion, supported by stable persistency (79.3%) and strong sales momentum in group voluntary benefits, network dental and vision, and group life and disability. Pretax adjusted earnings grew 1.4%, maintaining a healthy 20.4% margin.
Currency Pain Continues Unabated
The macroeconomic picture remains a stiff headwind. The average Yen/Dollar exchange rate weakened another 2.8% to 156.87. This clipped $0.02 off adjusted earnings per share and compressed Aflac Japan's reported USD net earned premiums by 6.4% YoY, completely wiping out the operational gains made by the sales team.
Variable Investment Income Lagging
While net investment income overall was stable at $902M (adjusted), management explicitly flagged that variable investment income ran $14 million below the company's long-term return expectations for the quarter. This metric is a minor but volatile swing factor for adjusted earnings and warrants monitoring if alternative asset classes continue to underperform.
Other KPIs
Accelerating. The margin expanded significantly from 31.8% a year ago. This 320 basis-point improvement was primarily driven by favorable benefits and claims, showcasing Aflac's strict underwriting standards and the highly profitable nature of its in-force book.
Stable. Aflac continues to aggressively shrink its share count, buying back $1.0 billion in stock (vs $900M a year ago) and paying $315M in dividends. Over the last four quarters, the company has deployed over $4.2 billion solely to buybacks.
Reversing. Down drastically from a $43 million gain in the prior year. Management blamed lower net investment income from reduced hedge benefits, higher interest expense, and operating costs related to closed blocks of business.
Guidance
Accelerating. Represents a 5.2% increase over the prior year, reaffirming the Board's aggressive commitment to cash returns.
Stable. Based on prior quarter guidance, management expects the structural runoff to continue offsetting new product sales through the end of 2026.
Stable. The Q1 result of 3.5% aligns perfectly with the lower end of management's previously stated full-year target range.
Accelerating. The Q1 actual of 35.0% sits comfortably in the upper half of this range, reflecting persistent structural profitability.
Key Questions
Japan Premium Inflection Horizon
With Japan new sales surging 25.5%, at what specific point in the future do mathematical models predict new business will finally overtake the paid-up policy runoff and generate positive Earned Premium growth?
U.S. Margin Pressure
U.S. segment expenses rose faster than revenues (5.4% vs 3.4%), driving the expense ratio up 70 bps. Is this a permanent cost of scaling new group/network businesses, or an anomaly?
Corporate Segment Headwinds
Corporate and Other adjusted earnings collapsed from $43M to breakeven due to hedge impacts and higher interest. Will this segment remain a drag on consolidated earnings for the rest of FY26?